HC Wainwright Forecasts Increased Earnings for Shattuck Labs

Posted by Brenda Bartman on Aug 13th, 2026

Shattuck Labs, Inc. (NASDAQ:STTK – Free Report) – Equities researchers at HC Wainwright upped their Q3 2026 earnings per share estimates for Shattuck Labs in a report released on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.09) per share for the quarter, up from their previous estimate of ($0.21). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.52) EPS.

Shattuck Labs (NASDAQ:STTK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12).

A number of other research firms also recently commented on STTK. Weiss Ratings upgraded shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Wedbush lifted their target price on Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Cantor Fitzgerald started coverage on Shattuck Labs in a report on Monday, April 27th. They set an “overweight” rating for the company. Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, JPMorgan Chase & Co. assumed coverage on Shattuck Labs in a research note on Friday, July 24th. They issued an “overweight” rating and a $10.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.12.

View Our Latest Stock Analysis on Shattuck Labs

Shattuck Labs Stock Performance

STTK opened at $7.49 on Thursday. The stock’s fifty day moving average is $6.32 and its 200-day moving average is $5.92. Shattuck Labs has a one year low of $0.76 and a one year high of $8.33. The company has a market capitalization of $574.33 million, a PE ratio of -14.69 and a beta of 1.08.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC boosted its position in Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Shattuck Labs in the 1st quarter worth about $81,000. Acadian Asset Management LLC raised its stake in shares of Shattuck Labs by 27.6% during the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after purchasing an additional 55,687 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Shattuck Labs during the 2nd quarter worth about $44,000. Finally, Jane Street Group LLC lifted its holdings in shares of Shattuck Labs by 2,510.8% during the 2nd quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after buying an additional 278,576 shares during the last quarter. 58.74% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Shattuck Labs news, insider Arundathy N. Pandite sold 30,000 shares of Shattuck Labs stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $7.01, for a total transaction of $210,300.00. Following the transaction, the insider owned 136,219 shares of the company’s stock, valued at $954,895.19. The trade was a 18.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Abhinav A. Shukla sold 23,365 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the sale, the insider directly owned 86,380 shares of the company’s stock, valued at $611,570.40. This trade represents a 21.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 53,875 shares of company stock worth $379,305. 8.79% of the stock is currently owned by company insiders.

More Shattuck Labs News

Here are the key news stories impacting Shattuck Labs this week:

Positive Sentiment: Positive Phase 1 data for SL-325: Shattuck reported a favorable safety profile, low immunogenicity, no evidence of DR3 agonism and durable blockade of TL1A binding. The results support the company’s view that SL-325 could potentially allow quarterly dosing and compete favorably in the inflammatory bowel disease market. Positive Phase 1 Data for SL-325
Positive Sentiment: Phase 2b trial approaching: The RECEPTIVE-CD1 study of SL-325 in approximately 232 Crohn’s disease patients is expected to begin in the third quarter of 2026. The primary efficacy data are expected in the first half of 2028, creating a major future catalyst if the trial demonstrates clinical benefit. SL-325 Crohn’s Trial Update
Positive Sentiment: Extended cash runway: Cash, cash equivalents and short-term investments totaled approximately $208.3 million at June 30, 2026, helped by an $86.2 million public offering and $57.1 million from exercised warrants. Management expects current resources to fund operations into 2029, reducing near-term financing risk.
Positive Sentiment: Pipeline expansion: Shattuck introduced SL-846, a DR3 x IL-23 receptor bispecific antibody, with initial Phase 1 data expected in 2027. This adds another potential growth opportunity beyond SL-325.
Neutral Sentiment: Earnings met expectations: Second-quarter EPS was a loss of $0.12, matching consensus. However, the company generated no revenue and remains dependent on clinical development and capital markets.
Neutral Sentiment: Analyst outlook remains constructive: HC Wainwright lowered its price target from $18 to $14 but maintained a Buy rating. Analysts overall have issued a Moderate Buy consensus, with targets substantially above the current trading level. Consensus Analyst Rating
Negative Sentiment: Higher operating losses: Second-quarter net loss increased to $15.2 million from $12.5 million a year earlier, while R&D spending rose to $11.7 million. The company’s valuation therefore continues to depend heavily on successful future trial results.

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.